The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Cardiovascular morbidity is a major burden in patients with type 2 diabetes. In the Steno-2 Study, we compared the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on modifiable risk factors for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. METHODS: The primary end point of this open, parallel trial was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization, and amputation. Eighty patients were randomly assigned to receive conventional treatment in accordance with national guidelines and 80 to receive intensive treatment, with a stepwise implementation of behavior modification and pharmacologic therapy that targeted hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention of cardiovascular disease with aspirin. RESULTS: The mean age of the patients was 55.1 years, and the mean follow-up was 7.8 years. The decline in glycosylated hemoglobin values, systolic and diastolic blood pressure, serum cholesterol and triglyceride levels measured after an overnight fast, and urinary albumin excretion rate were all significantly greater in the intensive-therapy group than in the conventional-therapy group. Patients receiving intensive therapy also had a significantly lower risk of cardiovascular disease (hazard ratio, 0.47; 95 percent confidence interval, 0.24 to 0.73), nephropathy (hazard ratio, 0.39; 95 percent confidence interval, 0.17 to 0.87), retinopathy (hazard ratio, 0.42; 95 percent confidence interval, 0.21 to 0.86), and autonomic neuropathy (hazard ratio, 0.37; 95 percent confidence interval, 0.18 to 0.79). CONCLUSIONS: A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although HRV testing is largely confined to the research setting, the CV reflex tests that assess changes in HRV during standardized clinical challenges such as deep breathing, Valsalva maneuver and supine-to-standing position remain the gold standard tests and are available for clinical care as well.547,614,626”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [626]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to traditional risk factors, hyperglycemia, hyperinsulinemia, and oxidative stress contribute to endothelial damage, leading to poor arterial function and greater susceptibility to atherogenesis ( 45 , 82 , 289 ).”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, studies in people with T2D and early CKD demonstrated the long-term bene fi t of multifactorial intervention on the development of microvascular and macrovascular complications and mortality.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (222,227,228).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [227]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (211,216,217).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [216]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people who already have diabetes, lifestyle modification and pharmacological treatment, as well as blood pressure and cholesterol control, can delay progression to complications and reduce mortality, or even help with remission, especially if started early.1,2,58–62”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [58]
Experimental — accuracy not yet measuredIn the citing paper
“The benefit of the intensive multifactorial intervention was demonstrated by a significant reduction in the incidence of microvascular complications after 4 years, and a significant 53% risk reduction in macrovascular complications after 8 years.455”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [455]
In the citing paper
“Angiotensin-converting enzyme inhibitors812), angiotensin Ⅱ receptor blockers813), and calcium channel antagonists814) have been reported to be effective for preventing cardiovascular events in patients with DM.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [813]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Research works printed but not linked: 2
- 10.1001/jama.241.19.2035 · DOI · Paper page
- 10.1001/archinte.151.6.1141 · DOI
Cited by
Sorted by citations
Items 501–600 of 1,025
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107
for the DIGAMI 2 Investigators, Mellbin, L., Malmberg, K., Norhammar, A., Wedel, H., & Rydén, L. (2011) · Diabetologia · doi:10.1007/s00125-011-2084-x · Cited by 107
Management of diabetic neuropathy
Cernea, S., & Raz, I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154867 · Cited by 110
Epidemiologic Methods in Physical Activity Studies
Lee, I. (2008) · doi:10.1093/acprof:oso/9780195183009.001.0001 · Cited by 110
Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management
Wolf, G., & Ritz, E. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000065639.19190.cf · Cited by 110
Yuyun, M. F. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh037 · Cited by 107
Can a Chronic Care Model Collaborative Reduce Heart Disease Risk in Patients with Diabetes?
Vargas, R. B., Mangione, C. M., Asch, S. M., KEESEY, J. W., Rosen, M., Schonlau, M., & Keeler, E. B. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-006-0072-5 · Cited by 106
Adiposopathy: Sick Fat Causes High Blood Sugar, High Blood Pressure and Dyslipidemia
Bays, H. E., Abate, N. I., & Chandalia, M. (2005) · Future Cardiology · doi:10.1517/14796678.1.1.39 · Cited by 106
Huang, E. S., Zhang, Q., Brown, S. E. S., Drum, M. L., Meltzer, D. O., & Chin, M. H. (2007) · Health Services Research · doi:10.1111/j.1475-6773.2007.00734.x · Cited by 106
Cardiac autonomic diabetic neuropathy
Schönauer, M., Thomas, A., Morbach, S., Niebauer, J., Schönauer, U., & Thiele, H. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.047 · Cited by 108
Association of Diabetic Neuropathy with Duration of Type 2 Diabetes and Glycemic Control
Nisar, M. U., Asad, A., Waqas, A., Ali, N., Nisar, A., Qayyum, M. A., Maryam, H., Javaid, M., & Jamil, M. (2015) · Cureus · doi:10.7759/cureus.302 · Cited by 107
Astrup, A. S., Nielsen, F. S., Rossing, P. R., Ali, S., Kastrup, J., Smidt, U., & Parving, H. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f06428 · Cited by 105
Self-citationThe potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Thomas, M. C. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30069-1 · Cited by 107
Chronic Kidney Disease in Diabetes
McFarlane, P. A., Cherney, D. Z. I., Gilbert, R. E., & Senior, P. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.11.004 · Cited by 112
Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm
DEEDWANIA, P. C., & Fonseca, V. A. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.05.018 · Cited by 107
G�de, P., Hildebrandt, P., Hess, G., Parving, H.-H., & Pedersen, O. (2005) · Diabetologia · doi:10.1007/s00125-004-1607-0 · Cited by 105
Self-citationGLP-1 receptor agonists: A clinical perspective on cardiovascular effects
Mundil, D., Cameron-Vendrig, A., & Husain, M. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441526 · Cited by 104
Khunti, K., Kosiborod, M., & Ray, K. K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13243 · Cited by 104
Trends in the Risk for Coronary Heart Disease Among Adults With Diagnosed Diabetes in the U.S.
Ford, E. S. (2011) · Diabetes Care · doi:10.2337/dc10-2251 · Cited by 105
Integrating albuminuria and GFR in the assessment of diabetic nephropathy
Jerums, G., Panagiotopoulos, S., Premaratne, E., & MacIsaac, R. J. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.91 · Cited by 104
Khalid, J. M., Raluy-Callado, M., Curtis, B., Boye, K. S., Maguire, A., & Reaney, M. D. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12265 · Cited by 106
Jarvis, J., Skinner, T. C., Carey, M., & Davies, M. J. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01098.x · Cited by 109
Intensive Multifactorial Intervention for Stable Coronary Artery Disease
Maron, D. J., Boden, W. E., O’Rourke, R. A., Hartigan, P. M., Calfas, K. J., Mancini, G. B. J., Spertus, J. A., Dada, M. R., Kostuk, W. J., Knudtson, M. L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.062 · Cited by 105
Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes
Carver, C. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706294259 · Cited by 105
What is the evidence that microalbuminuria is a predictor of cardiovascular disease events?
Yuyun, M. F., Adler, A., & Wareham, N. J. (2005) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000165895.90748.3b · Cited by 103
Chronic Kidney Disease in Diabetes
McFarlane, P. A., Gilbert, R. E., MacCallum, L., & Senior, P. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.037 · Cited by 102
What Do We Know and We Do Not Know About Cardiovascular Autonomic Neuropathy in Diabetes
Pop‐Busui, R. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9367-6 · Cited by 102
Ahmadi, M., Laumeier, I., Ihl, T., Steinicke, M., Ferse, C., Endres, M., Grau, A., Hastrup, S., Poppert, H., Palm, F., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30369-2 · Cited by 102
A1C and Cardiovascular Outcomes in Type 2 Diabetes
Colayco, D. C., Niu, F., McCombs, J. S., & Cheetham, T. C. (2010) · Diabetes Care · doi:10.2337/dc10-1318 · Cited by 103
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101
Perioperative diabetic and hyperglycemic management issues
Coursin, D. B., Connery, L. E., & Ketzler, J. T. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000115623.52021.c0 · Cited by 101
Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005
Marín, R., de la Sierra, Á., Armario, P., Campo, C., Banegas, J. R., & Gorostidi, M. (2005) · Medicina Clínica · doi:10.1157/13076402 · Cited by 106
Fenofibrate – A Potential Systemic Treatment for Diabetic Retinopathy?
Wong, T. Y., Simó, R., & Mitchell, P. L. R. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.013 · Cited by 100
Tablas de evaluación del riesgo coronario adaptadas a la población española. Estudio DORICA
Bartrina, J. A., Pérez‐Rodrigo, C., Foz, M., Mantilla, T., Serra‐Majem, L., Moreno, B., Monereo, S., Millán, J., & fase, G. C. P. E. E. D., II (2004) · Medicina Clínica · doi:10.1016/s0025-7753(04)75331-2 · Cited by 100
CD40/CD40L system and vascular disease
Santilli, F., Basili, S., Ferroni, P., & Davı̀, G. (2007) · Internal and Emergency Medicine · doi:10.1007/s11739-007-0076-0 · Cited by 100
Chronic kidney disease and diabetes
Pyram, R., Kansara, A., Banerji, M. A., & Loney‐Hutchinson, L. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.11.009 · Cited by 102
Shepherd, J., Betteridge, J. D., Gaal, L. V., & Panel, O. B. O. A. E. C. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x43677 · Cited by 100
Growth Factor Preconditioning Increases the Function of Diabetes-Impaired Mesenchymal Stem Cells
Khan, M., Akhtar, S., Mohsin, S., Khan, S. N., & Riazuddin, S. A. (2010) · Stem Cells and Development · doi:10.1089/scd.2009.0397 · Cited by 100
Chyun, D. A., Melkus, G. D., Katten, D. M., Price, W. J., Davey, J. A., Grey, N. J., Heller, G., & Wackers, F. J. T. (2006) · Biological Research For Nursing · doi:10.1177/1099800405285748 · Cited by 99
Rani, P. K., Raman, R., Gupta, A., Pal, S. S., Kulothungan, V., & Sharma, T. (2011) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-3-9 · Cited by 104
Manns, B., Tonelli, M. A., Zhang, J., Campbell, D. J. T., Sargious, P. M., Ayyalasomayajula, B., Clement, F. M., Johnson, J. A., Laupacis, A., Lewanczuk, R. Z., et al. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110755 · Cited by 105
Vasudevan, A. R., & Balasubramanyam, A. (2004) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2004.6.850 · Cited by 101
Cause-specific mortality in diabetes: recent changes in trend mortality
Khalil, C. A., Roussel, R., Mohammedi, K., Danchin, N., & Marre, M. (2012) · European Journal of Preventive Cardiology · doi:10.1177/1741826711409324 · Cited by 98
Karasu, Ç. (2010) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401004010240 · Cited by 99
Evaluación y tratamiento de la hipertensión arterial en España. Documento de consenso
de la Sierra, A., Gorostidi, M., Marín, R., Redón, J., Banegas, J. R., Armario, P., Puig, J. G., Zarco, J., Llisterri, J. L., Sanchís, C., et al. (2008) · Medicina Clínica · doi:10.1157/13124015 · Cited by 98
Recent advances in diabetic nephropathy
Marshall, S. M. (2004) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.021287 · Cited by 98
Pourcet, B., Fruchart, J., Staels, B., & Glineur, C. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.379 · Cited by 102
Yang, X. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.5.451 · Cited by 98
TSUIKI, M., TANABE, A., TAKAGI, S., NARUSE, M., & TAKANO, K. (2008) · Endocrine Journal · doi:10.1507/endocrj.k07e-177 · Cited by 97
Terry, T., Raravikar, K., Chokrungvaranon, N., & Reaven, P. D. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0238-6 · Cited by 98
Lloyd‐Jones, D. M., Huffman, M. D., Karmali, K. N., Sanghavi, D. M., Wright, J. S., Pelser, C. B., Gulati, M., Masoudi, F. A., & Goff, D. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.018 · Cited by 99
van Zuilen, A. D., Bots, M. L., Dülger, A., van der Tweel, I., van Buren, M., ten Dam, M. A. G. J., Kaasjager, K. A. H., Ligtenberg, G., Sijpkens, Y. W. J., Sluiter, H. E., et al. (2012) · Kidney International · doi:10.1038/ki.2012.137 · Cited by 96
Pharmacist-Led Group Medical Appointment Model in Type 2 Diabetes
Taveira, T. H., Friedmann, P. D., Cohen, L. B., Dooley, A. G., Khatana, S. A. M., Pirraglia, P. A., & Wu, W. (2009) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721709352383 · Cited by 97
3: Preventing complications of diabetes
Bate, K. L., & Jerums, G. (2003) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05655.x · Cited by 97
Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management
Williams, S., Raheim, S. A., Khan, M. I., Rubab, U., Kanagala, P., Zhao, S. S., Worthington, A., Brown, E. E., & Alam, U. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.09.002 · Cited by 102
Leiter, L. A. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.015 · Cited by 96
Glycated albumin levels predict long‐term survival in diabetic patients undergoing haemodialysis
Fukuoka, K., Nakao, K., Morimoto, H., NAKAO, A., Takatori, Y., Arimoto, K., Taki, M., Wada, J., & Makino, H. (2007) · Nephrology · doi:10.1111/j.1440-1797.2007.00864.x · Cited by 96
Risk of Diabetes Mellitus in Long-Term Survivors of Hodgkin Lymphoma
van Nimwegen, F. A., Schaapveld, M., Janus, C. P. M., Krol, A. D. G., Raemaekers, J. M. M., Kremer, L. C. M., Stovall, M., Aleman, B. M. P., & van Leeuwen, F. E. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.4379 · Cited by 95
Ueki, K., Sasako, T., Okazaki, Y., Miyake, K., Nangaku, M., Ohashi, Y., Noda, M., & Kadowaki, T. (2021) · Kidney International · doi:10.1016/j.kint.2020.08.012 · Cited by 94
The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
Newman, J. D., Vani, A. K., Alemán, J. O., WEINTRAUB, H. S., Berger, J. S., & Schwartzbard, A. Z. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.071 · Cited by 95
Physical activity and dietary interventions in diabetic neuropathy: a systematic review
Zilliox, L. A., & Russell, J. W. (2019) · Clinical Autonomic Research · doi:10.1007/s10286-019-00607-x · Cited by 99
Mannose-Binding Lectin and Mortality in Type 2 Diabetes
Hansen, T. K. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.18.2007 · Cited by 94
The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges
Davies, M. J. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802745 · Cited by 94
Tsai, J. H., Ford, E. S., Li, C., Zhao, G., Pearson, W. S., & Balluz, L. S. (2010) · Preventive Medicine · doi:10.1016/j.ypmed.2010.07.010 · Cited by 94
Glycemic and Risk Factor Control in Type 1 Diabetes
Eeg‐Olofsson, K., Cederholm, J., Nilsson, P. M., Guðbjörnsdóttir, S., & Eliasson, B. (2007) · Diabetes Care · doi:10.2337/dc06-1406 · Cited by 94
Khaw, K., Wareham, N. J., Bingham, S. A., & Luben, R. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.11.074 · Cited by 94
Exercise, Vascular Wall and Cardiovascular Diseases: An Update (Part 2)
Yung, L. M., Laher, I., Yao, X., Chen, Z. Y., Huang, Y., & Leung, F. P. (2009) · Sports Medicine · doi:10.2165/00007256-200939010-00004 · Cited by 93
Leehey, D. J., Collins, E., Kramer, H. J., Cooper, C., Butler, J., McBurney, C., Jelinek, C., Reda, D., Edwards, L., Garabedian, A., et al. (2016) · American Journal of Nephrology · doi:10.1159/000447703 · Cited by 93
Elley, C. R., Kenealy, T. W., Robinson, E., & Drury, P. L. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02581.x · Cited by 97
There really is an epidemic of type 2 diabetes
Colagiuri, S., Borch‐Johnsen, K., Glümer, C., & Vistisen, D. (2005) · Diabetologia · doi:10.1007/s00125-005-1843-y · Cited by 93
Outcomes of patients treated through the Canadian Fabry disease initiative
Sirrs, S. M., Bichet, D. G., Casey, R., Clarke, J. T. R., Lemoine, K., Doucette, S. P., & West, M. L. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.01.014 · Cited by 93
Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions
Asghar, O., Alam, U., Hayat, S. A., Aghamohammadzadeh, R., Heagerty, A. M., & Malik, R. A. (2012) · Current Cardiology Reviews · doi:10.2174/157340312803760749 · Cited by 94
Clinical Manifestations and Current Treatment options for Diabetic Neuropathies
CASELLINI, C. M., & Vinik, A. I. (2007) · Endocrine Practice · doi:10.4158/ep.13.5.550 · Cited by 95
Diabetic Retinopathy in Patients with Diabetic Nephropathy: Development and Progression
Jeng, C., Hsieh, Y., Yang, C., Yang, C., Lin, C., & Wang, I. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161897 · Cited by 96
Treatment of insulin resistance in diabetes mellitus
Lebovitz, H. E., & Banerji, M. A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.051 · Cited by 96
Diabetes Translation Research: Where Are We and Where Do We Want To Be?
Narayan, K. M. V., Benjamin, E. M., Gregg, E. W., Norris, S. L., & Engelgau, M. M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-11-200406010-00037 · Cited by 93
Treatment approach to type 2 diabetes: Past, present and future
Blaslov, K., Naranđa, F. S., Kruljac, I., & Renar, I. P. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i12.209 · Cited by 99
Toobert, D. J., Strycker, L. A., Glasgow, R. E., Barrera, M., & Angell, K. L. (2005) · Annals of Behavioral Medicine · doi:10.1207/s15324796abm2902_7 · Cited by 95
Revisiting the metabolic syndrome
Chew, G. T., Gan, S. K., & Watts, G. F. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00644.x · Cited by 92
Nakagami, T., Qiao, Q., Tuomilehto, J. O., Balkau, B., Tajima, N., Hu, G., & Borch‐Johnsen, K. (2006) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000183916.28354.69 · Cited by 92
Maeda, S., Kobayashi, M., Araki, S., Babazono, T., Freedman, B. I., Bostrom, M. A., Bailey, J. N. C., Toyoda, M., Umezono, T., Tarnow, L., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000842 · Cited by 95
Self-citationAvdic, T., Franzén, S., Zarrouk, M., Acosta, S., Nilsson, P. M., Gottsäter, A., Svensson, A., Guðbjörnsdóttir, S., & Eliasson, B. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007618 · Cited by 95
Dyslipidemia in diabetes mellitus and cardiovascular disease
Warraich, H. J., & Rana, J. S. (2017) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000120 · Cited by 95
Konst, R. E., Guzik, T. J., Kaski, J. C., Maas, A. H. E. M., & Elias‐Smale, S. E. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa009 · Cited by 91
Palmer, A. J., Annemans, L., Roze, S., Lamotte, M., Lapuerta, P., Chen, R. K., Gabriel, S., Carita, P., Rodby, R. A., de Zeeuw, D., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1897 · Cited by 91
Self-citationTobe, S. W. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050030 · Cited by 93
Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus
Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H., Joost, H., Kellerer, M., Kloos, C., Kunt, T., Nauck, M. A., et al. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1239559 · Cited by 93
Tacrolimus and Posttransplant Diabetes Mellitus in Renal Transplantation
van Hooff, J. P., Christiaans, M. H. L., & van Duijnhoven, E. M. (2005) · Transplantation · doi:10.1097/01.tp.0000157870.21957.e5 · Cited by 91
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Jaiswal, M., Divers, J., Urbina, E. M., Dabelea, D., Bell, R. A., Pettitt, D. J., Imperatore, G., Pihoker, C., Dolan, L. M., Liese, A. D., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12633 · Cited by 90
Voulgari, C., Katsilambros, N., & Tentolouris, N. (2011) · Metabolism · doi:10.1016/j.metabol.2011.02.014 · Cited by 90
Clinical inertia in general practice: widespread and related to the outcome of diabetes care
van Bruggen, R., Gorter, K. J., Stolk, R. P., Klungel, O. H., & Rutten, G. E. H. M. (2009) · Family Practice · doi:10.1093/fampra/cmp053 · Cited by 90
Kunutsor, S. K., Balasubramanian, V. G., Zaccardi, F., Gillies, C., Aroda, V. R., Seidu, S., & Khunti, K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15511 · Cited by 94
Gagliardino, J. J., Arrechea, V., Assad, D., Gagliardino, G. G., González, L., Lucero, S., Rizzuti, L., Zufriategui, Z., & Clark, C. M. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2368 · Cited by 90
Rolim, L. C., de Sá, J. R., Chacra, A. R., & Dib, S. A. (2008) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2008000400014 · Cited by 95
Wong, N. D., Patao, C., Wong, K., Malik, S., Franklin, S. S., & Iloeje, U. H. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113496828 · Cited by 92
Monnier, L., Colette, C., & Owens, D. R. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.962 · Cited by 89
Brambatti, M., Darius, H., Oldgren, J., Clemens, A., Noack, H., Brueckmann, M., Yusuf, S., Wallentin, L. C., Ezekowitz, M. D., Connolly, S. J., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.141 · Cited by 90
Complication characteristics between young-onset type 2 versus type 1 diabetes in a UK population
Song, S. H. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000044 · Cited by 91
Kloecker, D. E., Davies, M. J., Khunti, K., & Zaccardi, F. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3286 · Cited by 93
Metadata
- Authors
- Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- Herlev Hospital (DK)
- Roskilde Sygehus (DK)
- Aarhus University (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-01-30
- Volume
- 348
- Issue
- 5
- Pages
- 383-393
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139634859
- Cited by
- 4,378
- References
- 26
- Citations by year
- 2026: 47 · 2025: 71 · 2024: 108 · 2023: 110 · 2022: 102 · 2021: 137 · 2020: 142 · 2019: 133 · 2018: 171 · 2017: 143 · 2016: 158 · 2015: 169 · 2014: 198 · 2013: 184 · 2012: 235
- FWCI
- 178.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular disease, multifactorial intervention, microalbuminuria, tight glycemic control, hyperglycemia, hypertension, dyslipidemia, aspirin, myocardial infarction, stroke, kidney disease, retinopathy, autonomic neuropathy
- MeSH terms
- Amputation, Surgical, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Combined Modality Therapy, Diabetes Mellitus, Diabetes Mellitus, Type 2, Female, Humans, Hyperlipidemias, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Obesity, Risk Factors, Vitamins, Exercise, Smoking Cessation, Diet, Fat-Restricted, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
